The Biosimilar Red Tape Elimination Act aims to reduce regulatory barriers and administrative burdens associated with the approval and market entry of biosimilar drugs. By streamlining processes, the bill seeks to promote competition in the pharmaceutical market, potentially lowering drug prices and increasing patient access to these biologic medications.
Supporters of the Biosimilar Red Tape Elimination Act have praised it for its potential to enhance competition in the pharmaceutical industry. They argue that by making it easier for biosimilars to enter the market, the bill could lead to lower drug prices and improved access for patients, especially those relying on expensive biologic treatments.
Critics of the Biosimilar Red Tape Elimination Act express concerns that reducing regulatory oversight could compromise the safety and efficacy of biosimilar drugs. Some worry that hastening the approval process may lead to inadequate evaluation of these products, potentially putting patients at risk and undermining public trust in the healthcare system.
The Biosimilar Red Tape Elimination Act, sponsored by Mike Lee, presents significant potential conflicts of interest due to the substantial financial backing from the health professionals sector. With $600 million in donations from health professionals, who are directly affected by the legislation aimed at reducing regulatory burdens on biosimilars, there is a clear financial incentive for the sponsor to align legislative outcomes with donor interests. This raises concerns about whether the bill serves the public interest or primarily benefits the sponsor's donors. Additionally, the lack of transparency in lobbying activities, with several undisclosed amounts, further complicates the understanding of potential influences on the bill's progression. Voters should be aware that the financial ties between the sponsor and the health industry could lead to legislation that favors these donors over broader public health considerations.
These industries are both affected by this bill and among the sponsor's top donors.
| Industry | Match Type | Related Subject | Donations |
|---|---|---|---|
| Health Professionals (H01) | Sector | Health | $600,000,000 |
| Total from overlapping industries | $600,000,000 | ||
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| FRESENIUS KABI USA LLC | FRESENIUS KABI USA LLC | $1,100,000 |
| CONSEJO COORDINADOR EMPRESARIAL | IQOM STRATEGIC ADVISORS, LLC | $140,000 |
| IVANHOE ATLANTIC (FORMERLY HIGH POWER EXPLORATION INC.) | YORKTOWN SOLUTIONS | $120,000 |
| SKYRYSE, INC. | SKYRYSE, INC. | $70,000 |
| AIS HEALTHCARE | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | $20,000 |
| THE FERGUSON GROUP, LLC FOR CITY OF OCEANSIDE CA | EARL STOCKDALE | undisclosed |
| THE FERGUSON GROUP, LLC ON BEHALF OF WARD & SMITH (FOR BALD HEAD ISLAND) | EARL STOCKDALE | undisclosed |
| THE FERGUSON GROUP, LLC ON BEHALF OF WARD & SMITH, PA (FOR HOLDEN BEACH, NC) | EARL STOCKDALE | undisclosed |
| CORE POWER (US) INC. | INVARIANT LLC | undisclosed |
| ICON TECHNOLOGY, INC. | INVARIANT LLC | undisclosed |
| HUBBS-SEAWORLD RESEARCH INSTITUTE | HAMMER ASSOCIATES, LLC | undisclosed |
| THE POLICY SHOP LLC | JAVELIN ADVISORS LLC | undisclosed |
| NATIONAL ALLIANCE OF HEALTHCARE PURCHASER COALITIONS | NATIONAL ALLIANCE OF HEALTHCARE PURCHASER COALITIONS | undisclosed |
| EARTHSHIP CORPORATION | RED DOOR CONSULTING, LLC | undisclosed |
| KALE INFO SOLUTIONS INC | DAYBREAK STRATEGIES | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Mike Lee, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
